Diabetes Self-Management Blog

The Food and Drug Administration (FDA) is advising people who use the long-acting insulin detemir (brand name Levemir) to check their insulin vials to ensure that none are from a potentially dangerous batch that appeared on the U.S. market last week after having been stolen.

At least one of the stolen vials, which number roughly 129,000 in all, surfaced at a medical center in the Houston area. Because these vials did not go through the typical distribution channels, they may not have been stored and handled properly. The FDA has received one report of an adverse reaction resulting from use of one of the stolen vials.

To determine whether the insulin you are using comes from an affected lot, check the lot number on the side of the box of insulin or on the side of the vial. Insulin from lots XZF0036, XZF0037, and XZF0038 should not be used and should be replaced with insulin from another lot of Levemir.

For information about how to handle insulin vials from the stolen lots, contact the Novo Nordisk Customer Care Center at (800) 727-6500. And to learn more about the stolen vials, see the press release from Novo Nordisk.

POST A COMMENT       
  

Comments
  1. Thank you for such up to date info as the Levimir Insulin info. Have passed the website onto others re checking lot numbers of possibly stolen insulin. This is wonderful service, keep up such alerts. TU

    Posted by murray |
  2. Thanks for the information. I have a niece that uses this insulin so it is great knowing the information. We will check her vials of insulin.

    Posted by JULIE |

Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of Madavor Media, LLC., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.


Insulin & Other Injected Drugs
Dispelling the Myths of Insulin Therapy (08/01/14)
Insulin for Type 2 (07/14/14)
FDA Approves Inhalable Insulin (07/03/14)
FDA Approves Weekly Type 2 Diabetes Medicine (04/18/14)

Diane Fennell
Pistachios Offer Protection for People With Diabetes (08/29/14)
New Approach for Neuropathy Pain? (08/18/14)
New Metformin Combo Drug Approved for Type 2 Diabetes (08/13/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.